Entropic Analysis Of Hrv In Obese Children

Clinical Neurological Profie Of Patients With L...

Is Hypoalbuminemia A Prognostic Risk Factor For...

Prevalence Of Meropenem Susceptibility Among Gr...

Parental Attitudes And Practices About Circumc...

0 votes
Virulence In A Pseudomonas Syringae Strain With A Small Repertoire Of Predicted Effectors
Author: Kevin L. Hockett, Marc T. Nishimura, Erick Karlsrud , Kevin Dougherty, And David A. Baltrus
Publisher: Derivative Works
45 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1943-0264
DOI: 10.1101/000869
Follow this publisher

Share this publication:


Astract Both type III effector proteins and non-ribosomal peptide toxins play important roles for Pseudomonas syringae pathogenicity in host plants, but if and how these virulence pathways interact to promote infection remains unclear. Genomic evidence from one clade of P. syringae suggests a tradeoff between the total number of type III effector proteins and presence of syringomycin, syringopeptin, and syringolin A toxins. Here we report the complete genome sequence from P. syringae CC1557, which contains the lowest number of known type III effectors to date and has also acquired a highly similar toxin to syringomycin through horizontal transfer. We demonstrate that this strain is pathogenic on Nicotiana benthamiana and that both the type III secretion system and a new type III effector family, hopBJ1, contribute to virulence. Taken together, our results provide independent evolutionary confirmation of a negative correlation between type III effector repertoires and some non-ribosomal peptide toxins while also highlighting how genomic synteny can be used to identify novel virulence proteins.

About the publisher:

We are a publishing house devoted to reuse CC-BY licensed published materials.


Using CC-BY licenses:


  • Adapt — remix, transform, and build upon the material
  • for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.


  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others
    from doing anything the license permits.


  • You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
  • No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Select a payment method